| pubmed-article:11091219 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11091219 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:11091219 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:11091219 | lifeskim:mentions | umls-concept:C0002874 | lld:lifeskim |
| pubmed-article:11091219 | lifeskim:mentions | umls-concept:C0021079 | lld:lifeskim |
| pubmed-article:11091219 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:11091219 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:11091219 | lifeskim:mentions | umls-concept:C0439661 | lld:lifeskim |
| pubmed-article:11091219 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:11091219 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11091219 | pubmed:dateCreated | 2000-12-13 | lld:pubmed |
| pubmed-article:11091219 | pubmed:abstractText | A total of 100 children under the age of 17 years with acquired aplastic anaemia (AA) were initially treated with immunosuppressive therapy (IST) (n = 63) or bone marrow transplantation (BMT) (n = 37) from an HLA-matched family donor. The projected 10-year survival rates were 55 +/- 8% and 97 +/- 3% respectively (P = 0.004). Because the IST group included 11 non-responders who were salvaged by BMT from an HLA-matched unrelated donor, we compared failure-free survival (FFS) between the groups. The probability of FFS at 10 years was 97 +/- 3% for the BMT group, compared with 40 +/- 8% for the IST group (P = 0.0001). Seven patients evolved to myelodysplastic syndrome (MDS) with monosomy 7 and the estimated cumulative incidence of MDS 10 years after diagnosis was 20 +/- 7% in the IST group. We compared the outcome of children treated with IST during the two consecutive periods of 1983-91 (group A, n = 40) and 1991-8 (group B, n = 23) to assess the impact of combined therapy with antithymocyte globulin and cyclosporin. The probability of FFS at 7 years follow-up was the same in the two groups (50 +/- 8% vs. 40 +/- 15%, P = 0.40). We recommend BMT as first-line therapy in paediatric severe AA patients with an HLA-matched family donor. Alternative donor BMT is recommended as salvage therapy in patients who relapse or do not respond to initial IST. | lld:pubmed |
| pubmed-article:11091219 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11091219 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11091219 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11091219 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11091219 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11091219 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11091219 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11091219 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:11091219 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:11091219 | pubmed:author | pubmed-author:KatoKK | lld:pubmed |
| pubmed-article:11091219 | pubmed:author | pubmed-author:TakahashiYY | lld:pubmed |
| pubmed-article:11091219 | pubmed:author | pubmed-author:KudoKK | lld:pubmed |
| pubmed-article:11091219 | pubmed:author | pubmed-author:KojimaSS | lld:pubmed |
| pubmed-article:11091219 | pubmed:author | pubmed-author:InabaJJ | lld:pubmed |
| pubmed-article:11091219 | pubmed:author | pubmed-author:MatsuyamaTT | lld:pubmed |
| pubmed-article:11091219 | pubmed:author | pubmed-author:HoribeKK | lld:pubmed |
| pubmed-article:11091219 | pubmed:author | pubmed-author:YoshimiAA | lld:pubmed |
| pubmed-article:11091219 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11091219 | pubmed:volume | 111 | lld:pubmed |
| pubmed-article:11091219 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11091219 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11091219 | pubmed:pagination | 321-8 | lld:pubmed |
| pubmed-article:11091219 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:meshHeading | pubmed-meshheading:11091219... | lld:pubmed |
| pubmed-article:11091219 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11091219 | pubmed:articleTitle | Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. | lld:pubmed |
| pubmed-article:11091219 | pubmed:affiliation | Department of Developmental Paediatrics, Nagoya University School of Medicine, Japan. kojimas@med.nagoya-u.ac.jp | lld:pubmed |
| pubmed-article:11091219 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11091219 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11091219 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11091219 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11091219 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11091219 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11091219 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11091219 | lld:pubmed |
